Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152).

A series of compounds were designed and synthesized as antagonists of cIAP1/2, ML-IAP, and XIAP based on the N-terminus, AVPI, of mature Smac. Compound 1 (GDC-0152) has the best profile of these compounds; it binds to the XIAP BIR3 domain, the BIR domain of ML-IAP, and the BIR3 domains of cIAP1 and cIAP2 with K(i) values of 28, 14, 17, and 43 nM, respectively. These compounds promote degradation of cIAP1, induce activation of caspase-3/7, and lead to decreased viability of breast cancer cells without affecting normal mammary epithelial cells. Compound 1 inhibits tumor growth when dosed orally in the MDA-MB-231 breast cancer xenograft model. Compound 1 was advanced to human clinical trials, and it exhibited linear pharmacokinetics over the dose range (0.049 to 1.48 mg/kg) tested. Mean plasma clearance in humans was 9 ± 3 mL/min/kg, and the volume of distribution was 0.6 ± 0.2 L/kg.

[1]  S. Srinivasula,et al.  Mechanism of XIAP-mediated inhibition of caspase-9. , 2003, Molecular cell.

[2]  C. Duckett,et al.  Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. , 2005, The Journal of clinical investigation.

[3]  M. Bertrand,et al.  cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. , 2008, Molecular cell.

[4]  J. Zha,et al.  Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. , 2008, Cancer research.

[5]  Shaomeng Wang.  Design of small-molecule Smac mimetics as IAP antagonists. , 2010, Current topics in microbiology and immunology.

[6]  Stephen W. Fesik,et al.  NMR Structure and Mutagenesis of the Third Bir Domain of the Inhibitor of Apoptosis Protein XIAP* , 2000, The Journal of Biological Chemistry.

[7]  K. Schulze-Osthoff,et al.  Apoptosis-based therapies and drug targets , 2005, Cell Death and Differentiation.

[8]  Stephen B. H. Kent,et al.  Efficient method for the preparation of peptoids [oligo(N-substituted glycines)] by submonomer solid-phase synthesis , 1992 .

[9]  G. Mills,et al.  XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. , 2001, Cancer research.

[10]  R. Korneluk,et al.  The inhibitors of apoptosis: there is more to life than Bcl2 , 2003, Oncogene.

[11]  W. Fairbrother,et al.  c‐IAP1 and UbcH5 promote K11‐linked polyubiquitination of RIP1 in TNF signalling , 2010, The EMBO journal.

[12]  Lily Yang,et al.  Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. , 2003, Cancer research.

[13]  W. Fairbrother,et al.  Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. , 2006, ACS chemical biology.

[14]  K. Das,et al.  Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP. , 2005, The Biochemical journal.

[15]  Susan M. Keating,et al.  Putting the pieces together: contribution of fluorescence polarization assays to small-molecule lead optimization , 2000, Photonics West - Biomedical Optics.

[16]  Jongdae Lee,et al.  IAP Suppression of Apoptosis Involves Distinct Mechanisms: the TAK1/JNK1 Signaling Cascade and Caspase Inhibition , 2002, Molecular and Cellular Biology.

[17]  D. Vučić,et al.  (Un)expected roles of c-IAPs in apoptotic and NFκB signaling pathways , 2008 .

[18]  M. Distefano,et al.  Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP). , 2003, Biochemistry.

[19]  W. Fairbrother,et al.  c-IAP1 and c-IAP2 Are Critical Mediators of Tumor Necrosis Factor α (TNFα)-induced NF-κB Activation* , 2008, Journal of Biological Chemistry.

[20]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[21]  Vickie Tsui,et al.  Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold. , 2009, Journal of medicinal chemistry.

[22]  Masahiko Miura,et al.  Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. , 2002, Cancer research.

[23]  Su Qiu,et al.  Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. , 2010, Journal of medicinal chemistry.

[24]  A. Schimmer.  Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical Practice , 2004, Cancer Research.

[25]  D J Rance,et al.  The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.

[26]  W. Fairbrother,et al.  The Inhibitor of Apoptosis Proteins as Therapeutic Targets in Cancer , 2007, Clinical Cancer Research.

[27]  G. Salvesen,et al.  ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas , 2000, Current Biology.

[28]  S. Hymowitz,et al.  Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists. , 2009, ACS chemical biology.

[29]  J. Waring,et al.  Both cIAP1 and cIAP2 regulate TNFα-mediated NF-κB activation , 2008, Proceedings of the National Academy of Sciences.

[30]  Robert L Moritz,et al.  Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins , 2000, Cell.

[31]  R. Korneluk,et al.  The inhibitors of apoptosis (IAPs) as cancer targets , 2007, Apoptosis.

[32]  J. Flygare,et al.  Development of novel drugs targeting inhibitors of apoptosis. , 2009, Future oncology.

[33]  Xiaodong Wang,et al.  Structural and biochemical basis of apoptotic activation by Smac/DIABLO , 2000, Nature.

[34]  J. Balian,et al.  Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[35]  Tao Zhang,et al.  A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. , 2011, Journal of medicinal chemistry.

[36]  Vishva M. Dixit,et al.  IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis , 2007, Cell.

[37]  G. Salvesen,et al.  Apoptosis: IAP proteins: blocking the road to death's door , 2002, Nature Reviews Molecular Cell Biology.

[38]  J. Inazawa,et al.  Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. , 2001, Cancer research.

[39]  Stephen F. Betz,et al.  Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain , 2000, Nature.

[40]  Saul H Rosenberg,et al.  Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. , 2004, Journal of medicinal chemistry.

[41]  V S Lamzin,et al.  ARP/wARP and molecular replacement. , 2001, Acta crystallographica. Section D, Biological crystallography.

[42]  Xiaodong Wang,et al.  A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell Death , 2004, Science.

[43]  C. Ly,et al.  Antagonists of inhibitor of apoptosis proteins based on thiazole amide isosteres. , 2010, Bioorganic & medicinal chemistry letters.

[44]  Christian Stehlik,et al.  Activation of NF-κB by XIAP, the X Chromosome-linked Inhibitor of Apoptosis, in Endothelial Cells Involves TAK1* , 2000, The Journal of Biological Chemistry.

[45]  Yaqoub Ashhab,et al.  The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. , 2004, Seminars in cancer biology.

[46]  Liu Liu,et al.  Potent bivalent Smac mimetics: effect of the linker on binding to inhibitor of apoptosis proteins (IAPs) and anticancer activity. , 2011, Journal of medicinal chemistry.

[47]  Stephen W. Fesik,et al.  NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP , 1999, Nature.

[48]  R. Liddington,et al.  Structural Basis for the Inhibition of Caspase-3 by XIAP , 2001, Cell.

[49]  M. Malim,et al.  Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[50]  E. Alnemri,et al.  X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility , 2008, Nature Cell Biology.

[51]  A. Goldberg,et al.  c-IAP1 cooperates with Myc by acting as a ubiquitin ligase for Mad1. , 2007, Molecular cell.

[52]  W. Fairbrother,et al.  Small-molecule pan-IAP antagonists: a patent review , 2010, Expert opinion on therapeutic patents.

[53]  Emad S. Alnemri,et al.  A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis , 2001, Nature.

[54]  Yongge Zhao,et al.  Tumor Necrosis Factor Receptor 2 Signaling Induces Selective c-IAP1-dependent ASK1 Ubiquitination and Terminates Mitogen-activated Protein Kinase Signaling* , 2007, Journal of Biological Chemistry.

[55]  D. Vaux,et al.  The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3– and caspase 9–interacting sites , 2002, The Journal of cell biology.

[56]  J C Reed,et al.  Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases , 1999, The EMBO journal.

[57]  Young Chul Park,et al.  Structural Basis of Caspase Inhibition by XIAP Differential Roles of the Linker versus the BIR Domain , 2001, Cell.

[58]  J C Reed,et al.  A Single BIR Domain of XIAP Sufficient for Inhibiting Caspases* , 1998, The Journal of Biological Chemistry.

[59]  D. Perrier,et al.  Noncompartmental determination of the steady-state volume of distribution for any mode of administration. , 1982, Journal of pharmaceutical sciences.

[60]  Stephanie Birkey Reffey,et al.  X-linked Inhibitor of Apoptosis Protein Functions as a Cofactor in Transforming Growth Factor-β Signaling* , 2001, The Journal of Biological Chemistry.

[61]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.